These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2079249)

  • 1. [Mucin markers in metastatic breast cancer].
    Bieglmayer C; Breitenecker G; Szepesi T
    Gynakol Rundsch; 1990; 30 Suppl 1():142-4. PubMed ID: 2079249
    [No Abstract]   [Full Text] [Related]  

  • 2. Serological tumor markers for monitoring breast cancer.
    Sölétormos G
    Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127
    [No Abstract]   [Full Text] [Related]  

  • 3. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor markers in breast cancer.
    Tondini C; Hayes DF; Kufe DW
    Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
    Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
    Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tumor markers in breast cancer].
    Harada Y; Ohuchi N; Ishida T; Ohnuki K
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1035-40. PubMed ID: 11478135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum marker combinations in human breast cancer (review).
    Lamerz R; Stieber P; Fateh-Moghadam A
    In Vivo; 1993; 7(6B):607-13. PubMed ID: 8193281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Increase in serum mucin-like carcinoma-associated antigen (MCA) in patients with chronic liver diseases].
    Soriano A; Pombo L; Sagredo E; Ruibal A
    Med Clin (Barc); 1988 Nov; 91(17):675. PubMed ID: 3230974
    [No Abstract]   [Full Text] [Related]  

  • 10. High BCM serum levels in patients with non breast tumors: first results.
    Allende T; Vizoso F; Roiz C; Fueyo A; Lennartz L; Ruibal A
    Bull Cancer; 1990; 77(10):1031-2. PubMed ID: 2249013
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
    Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
    Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour marker measurements in the diagnosis and monitoring of breast cancer.
    Cheung KL; Graves CR; Robertson JF
    Cancer Treat Rev; 2000 Apr; 26(2):91-102. PubMed ID: 10772967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor markers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
    Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB
    J BUON; 2007; 12(4):487-92. PubMed ID: 18067207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Small intestinal mucin antigen (SIMA)].
    Endo T; Akashi H; Arimura Y; Shinomura Y
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():772-4. PubMed ID: 20960870
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.
    Alix-Panabières C; Brouillet JP; Fabbro M; Yssel H; Rousset T; Maudelonde T; Choquet-Kastylevsky G; Vendrell JP
    J Immunol Methods; 2005 Apr; 299(1-2):177-88. PubMed ID: 15914200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers.
    Cheung KL; Robertson FR
    Minerva Chir; 2003 Jun; 58(3):297-303. PubMed ID: 12955047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Considerations in rational use of tumor markers in breast carcinoma].
    Crombach G
    Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer.
    Goodale D; Phay C; Brown W; Gray-Statchuk L; Furlong P; Lock M; Chin-Yee I; Keeney M; Allan AL
    Cytometry B Clin Cytom; 2009 Mar; 76(2):107-17. PubMed ID: 18727054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating mucin in breast carcinoma and automated leukocyte counts.
    Machicao CN; Schaub CR; Farhi DC
    Hematol Pathol; 1988; 2(3):159-61. PubMed ID: 2851581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.